LZL50
LZL50 is an orally effective human caseinolytic protease P (hClpP) activator with an EC50 of 0.29 μM. LZL50 activates hClpP, a serine protease that mediates mitochondrial quality control by degrading damaged or misfolded mitochondrial proteins. LZL50 exhibits antitumor activity in a breast cancer xenograft mouse model. LZL50 can be used in research related to breast cancer.
For research use only. We do not sell to patients.
- Formula: C31H33F4N3O2
- Molecular Weight:555.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
LZL50 (5 nM-30 μM; 72 h) inhibits the growth of MDA-MB-231 cells with an IC50 of 0.30 ± 0.04 μM after 72 h of treatment[1].
LZL50 (1.0 μM; up to 120 min) has moderate metabolic stability in human liver microsomes, with a CLint of 46.2 mL/min/kg and a T1/2 of 39 min[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | Cmax | Tmax | AUC0-t | AUC0-∞ | T1/2 |
|---|---|---|---|---|---|---|---|
| Rat[1] | 15 mg/kg | p.o. | 1939.24 ng/mL | 1.12 h | 18403.92 ng·h/mL | 19010.67 ng·h/mL | 4.37 h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 5 weeks old)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:p.o.; daily; 15 days
-
Result:Nearly completely suppressed tumor growth at 20 mg/kg.
Showed no significant body weight loss in any treatment group during the 15-day treatment period.
Chemical Information
-
Molecular Weight 555.61
-
Formula C31H33F4N3O2
-
SMILES
O=C1N([C@H](CC2=CC=C(C=C21)CC3=CC=C(C=C3)F)COCCN4CCNCC4)CC5=CC=C(C=C5)C(F)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)